Reviewer's report

Title: Additional Diagnostic value of Tumor markers in Cytological fluid for Diagnosis of non-small-cell lung cancer

Version: 1 Date: 23 May 2012

Reviewer: Xavier Filella

Reviewer's report:

The manuscript contains valuable information about the usefulness of tumor markers in the diagnosis of lung cancer. However, some minor changes may increase the value of this manuscript:

The authors explain that tumor markers are present in high concentrations in cytological fluid. However, regarding CEA, significant differences are observed in serum but not in cytological fluid. Do you have an explanation for it?

Please, show the information about the stage of patients diagnosed of lung cancer. Are there differences in accuracy between patients with initial and advanced stages?

Add VAT in the list of abbreviations

The histology of 66% of patients is adenocarcinoma and authors indicate that “Therefore, the value of cytological tumor markers determined in this study might be limited for cell types other than adenocarcinoma”. It may be interesting to compare results about the usefulness of tumor markers (and particularly, CYFRA 21.1) and NAB for patients with adenocarcinoma with results for patients with other type of histology.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests